AdBio partners’ Post

Today marks the first day of trading in Trill Impact’s portfolio company Cinclus Pharma on Nasdaq Stockholm. The listing is an important milestone that enables continued development of the company’s drug candidate linaprazan glurate, which aims to improve the medical outcomes for patients suffering from severe stomach acid-related disorders worldwide.   Nina Rawal, Partner at Trill Impact Advisory and Co-head of Trill Impact Ventures was present when the opening bell rang this morning.   “It is of course very exciting to see Cinclus Pharma being listed on Nasdaq Stockholm today. To us, the fact that Cinclus Pharma has attracted investor interest in the current financial climate, is a great testament to the quality of the asset and the strong management team. When Trill Impact invested in Cinclus Pharma a couple of years back, we were confident that the company had the potential to become a global leader in the treatment of severe gastric acid-related disease. Since then, the company has reported strong Phase II data and is now ready to move into the final stage of clinical development". Read more about the #IPO here: https://lnkd.in/d7tvcBPC #impactinvesting #biotech #healthcare #lifescience #SDG3

GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional investment by Bristol Meyers Squibb (BMS) to further support the development of its innovative platform to enable high-throughput design and production of drug development candidates for fast and deep degradation of pathogenic proteins. VISCHER advised GlycoEra on all legal issues related to the transaction. The VISCHER team included (pictured from left to right) Matthias Staehelin Partner, Corporate/M&A, Pauline Pfirter, Senior Associate, Corporate/M&A and Timothy Woodtli Associate, Corporate/M&A. Read the article >> https://lnkd.in/dpb-Yurm #Legalcommunitych #legaladvisor #financinground

Discover how leading life science companies are overcoming challenges and raising significant funds to drive innovation! This panel will feature industry leaders discussing their unique scientific pursuits, products, and the financial and regulatory hurdles in today’s competitive life sciences market. 🎤 Speakers include: Jang-Ho Cha, Latus Therapeutics Josh Muntner, CFO, Imvax, Inc. Moderated by John Pennett, EisnerAmper Advisory Services. Join us for this insightful session at the Philly Builds Bio+ Third Annual Symposium! 🔗 Register today: phillybuildsbio.org #PhillyBuildsBio #LifeSciences #InvestmentOpportunities #FinancingSuccess #BiotechInnovation

MST Financial is proud to have supported Opthea Ltd (OPT.ASX) acting as Sole Lead Manager to the company’s A$227 million capital raising – the largest pre-Phase 3 readout biotech raise ever in Australia (ex CSL). The capital raising comprised of a A$10.0 million Institutional Placement and a $217.3 million accelerated non renounceable entitlement offer (ANREO). Proceeds of the offer will be used to continue advancing clinical development of OPT-302 for the treatment of wet AMD, including progressing the Phase 3 clinical program, CMC (chemistry, manufacturing, and controls) activities and Biologics License application (BLA) preparations. OPT-302 treats wet AMD, the leading cause of irreversible blindness, by improving vision in patients. #MSTFinancial #OptheaLtd #OPT #growthcapital #australianequities #ASX #finance #retinalspecialists #wetAMD #ophthalmology #macular #degeneration

I am participating LSN Webinar to share my two cents on growing interest of JP startups/biotechs on Go-to-market strategy abroad and what improvement is needed to achieve it.

𝐁𝐞 𝐁𝐢𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐁𝐂𝐌 𝐏𝐫𝐨𝐠𝐫𝐚𝐦𝐬 𝐰𝐢𝐭𝐡 $𝟖𝟐𝐌 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐚𝐧𝐝 𝐊𝐞𝐲 𝐇𝐢𝐫𝐞𝐬 Be Biopharma Be Biopharma has achieved significant milestones with BE-101 entering the clinic and BE-102 unveiled as a candidate for Hypophosphatasia (HPP). BE-101, designed to deliver durable Factor IX for Hemophilia B, recently received FDA Fast Track Designation and is now enrolling patients in the Phase 1/2 BeCoMe-9 trial. BE-102 shows potential to treat HPP by generating sustained ALP levels, addressing a severe unmet need. The company secured $82 million in new financing from leading investors, including ARCH Venture Partners, Atlas Venture, and Bristol Myers Squibb, to advance these programs. Be Bio also welcomed Suha Patel Suhas Patel and Kiran Patki, MD, Kiran C. Patki, MD, MSc, FFPM adding valuable clinical and commercial expertise as it transitions to a clinical-stage company. #Biotech #GeneticMedicine #HemophiliaB #Hypophosphatasia #BeBio #BCMPlatform #Funding

Our CEO Ashley Zehnder will be speaking at the LSX USA Congress in Boston this Thursday, September 12, 11:00am - 11:50am at the Hynes Convention Center. What is Required to Scale? Fast-Tracking Biotech Growth When transitioning into a growth-stage biotech, it’s important to consider your strategy top succeed. Biotech companies needing to address unmet medical needs, without careful evaluation of market potential, there is a risk of failure. Staying virtual and outsourcing work to CROs vs building and carrying out in-house research Most important factors to remember when scaling up The people factor in building and growing business The panel will be moderated by Jenny Holt, Chief Development Officer, Ray Therapeutics, Inc. and include speakers: Vik Chawla, Managing Director, Portfolio Strategy & Transactions, Syneos Health Samta Kundu, COO, Strand Therapeutics Wyatt McDonnell, CEO, Infinimmune, Inc. Ashley Zehnder, Ph.D., CEO, Fauna Bio Minji Kim, CBO, Mineralys Therapeutics, Inc. More info here: https://lnkd.in/eQjBmQCb

We're at the RSC Fragments Meeting in Hinxton today and tomorrow - come and say hello if you want to talk about fragments and how we can help you integrate them into your drug discovery projects. #fragments24 #drugdiscovery #FBLD #DEL

🚀 $94m Series A!! The ADC field continues to soar. 🌟 It's no secret that Antibody-Drug Conjugates (ADCs) have been igniting the biopharma industry with their groundbreaking potential. Recent quarters witnessed Lilly making strategic moves, clinching two acquisitions in the ADC domain. Moreover, Bristol Myers Squibb's noteworthy $100 million upfront investment last year to acquire a Phase I-cleared ADC, sharing similarities with Firefly’s approach, underscores the immense promise of this therapeutic frontier. However, what truly makes this Series A funding remarkable is the innovative integration of degraders into ADCs, signaling a nascent yet profoundly transformative approach. Congratulations to Firefly Bio for this milestone achievement, and here's to the journey of pioneering advancements in healthcare! 🌐💡 #ADC #Biopharma #Innovation #SeriesA #HealthcareInvestment

We've received firm commitments from institutional and high net worth investors to raise approximately A$5.0 million via a two-tranche placement at A$0.028 per share. Funds raised will be used to provide certainty of funding for the completion of Phase 2 clinical trials in myelofibrosis, myelodysplastic syndrome, skin scarring, and iRBD/Parkinson’s disease. Gary Phillips, Chief Executive Officer, commented, “It has been an exciting period for the company as we rapidly closed in on our recruitment targets for the Phase 2 multinational study targeting MF, with 14 out of 15 patients now recruited and the last review of the data by the Safety Monitoring Committee resulting in a unanimous vote to continue the study. In addition, we completed the final stages of exit from the MBU, achieving anticipated cost savings of $14m per annum. The unexpected challenge by Arna Pharma of amounts claimed by Syntara under the agreement signed by both parties in October 2023 created an unacceptable level of uncertainty around funding of our active clinical trial programs. I am grateful for the strong support of our shareholders to ensure that we can continue to deliver key data from our phase 2 programs and the multiple opportunities that flow from that. Syntara has appointed external counsel to actively pursue legal remedies, as necessary.” Read the full ASX Announcement here: https://lnkd.in/gnB2Gmfn #SNT #Syntara #biotech #ASX #DrugDevelopment #biotechnology #cancerresearch #smallcaps #smallcapstocks